US FDA flags dosing risks from compounded versions of Novo's weight-loss drug
-The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk (NYSE:
The FDA flagged the higher risk to patients from the use of compounded drugs, which may contain additional ingredients, and may contribute to potential medication errors. It urged healthcare providers and compounders to provide the appropriate syringe size and counsel patients on how to measure the dose.
The explosive demand has created a huge shortage and fueled a booming global market for cheaper versions, sometimes even counterfeits. Semaglutide, the key ingredient in Wegovy and Ozempic, belongs to the GLP-1 class of drugs, which work by helping control blood sugar levels and triggering a feeling of fullness.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Pulls Food Additive in Citrus Sodas Over Health RisksThe Food and Drug Administration has revoked its authorization allowing brominated vegetable oil (BVO) to be used in food, following new data.
Read more »
Dog and Cat Food Sold Nationwide Recalled Over Major Health Risks, FDA SaysDigital destination for sophisticated men & women. Live your best life with expert tips and news on health, food, sex, relationships, fashion and lifestyle.
Read more »
FDA approves Eli Lilly's Alzheimer's drug that can modestly slow diseaseEli Lilly's Kisunla is the second treatment available in the U.S. that has been shown in trials to modestly slow a decline in memory.
Read more »
Lilly's Alzheimer's drug gets FDA nodDonanemab, under the brand name Kisunla, is the second drug of its kind to win FDA approval.
Read more »
FDA bans food additive found in citrusy sports drinks and sodasA new study is raising concerns about a popular sugar substitute called xylitol. Researchers say xylitol, found in many foods, candies and even toothpaste, is associated with an increased risk for heart attack and stroke. NBC News' Anne Thompson reports.
Read more »
FDA Approves Donanemab for Early Alzheimer'sThe FDA has approved the anti-amyloid donanemab for early symptomatic Alzheimer's, which includes MCI or mild dementia stage of disease, with confirmed amyloid pathology.
Read more »